Financial Results for the Quarter ended June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs reported total revenue of ₹121.03 lakhs for Q1 FY26, jumping from just ₹13.40 lakhs in Q1 FY25, driven almost entirely by a sharp rise in revenue from operations (₹121.03 lakhs vs ₹10.40 lakhs). Profit after tax rose to ₹3.74 lakhs (EPS ₹0.071) compared to ₹1.08 lakhs (EPS ₹0.02) a year ago. Total expenses climbed to ₹117.29 lakhs, mainly on stock-in-trade purchases of ₹112.25 lakhs, which pulled the operating margin down. Cash flow from operations turned positive at ₹9.70 lakhs versus a ₹229.02 lakh outflow for the full previous year. The statutory auditor (PPKG & Co) issued an unmodified limited review report.
Strong top-line growth is a positive signal for shareholders, but thin margins and a negative other equity (₹84.97 lakhs accumulated losses) suggest the company is still in an early recovery phase. Watch receivables closely as they more than doubled to ₹230.81 lakhs, which could pressure future cash flows.